Investors

Press Releases

Date Title View
Toggle Summary Momenta Pharmaceuticals Announces FDA Warning Letter to Contracted Glatopa® (glatiramer acetate injection) Fill/Finish Manufacturer
  Approval of the Glatopa 40 mg ANDA will be dependent on resolution of Pfizer facility compliance issues Warning letter does not restrict the production or shipment of Glatopa 20 mg CAMBRIDGE, Mass. , Feb. 17, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc.
View HTML
Toggle Summary Momenta Pharmaceuticals Announces HSR Clearance for Collaboration and License Agreement with CSL
CAMBRIDGE, Mass. , Feb. 17, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2016 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass. , Feb. 07, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the fourth quarter and year ended December 31, 2016 before the U.S.
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the Leerink Partners 6th Annual Global Healthcare Conference
CAMBRIDGE, Mass. , Feb. 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Leerink Partners 6th Annual Global Healthcare Conference.
View HTML
Toggle Summary Momenta Pharmaceuticals Announces District Court Decision to Invalidate Teva Pharmaceuticals Patents in COPAXONE® (glatiramer acetate injection) 40 mg/mL Litigation
Four of Teva's Orange-Book listed patents ruled invalid due to obviousness
View HTML
Toggle Summary Momenta Provides Year-End 2016 Corporate Update
-- New collaboration and license agreement with CSL to develop Fc multimer programs, including M230, with a $50M upfront license fee -- -- Agreement with Shire to receive full rights to M923 and a $51M one-time return payment -- CAMBRIDGE, Mass. , Jan.
View HTML
Toggle Summary Momenta and CSL Announce Collaboration and License Agreement to Develop Fc Multimer Programs, Including M230, a Selective Immunomodulator of Fc Receptors
--Momenta to receive $50 million upfront license fee and up to $550 million in potential milestone payments from CSL--              --Momenta to host a conference call for its investors today at 4:30 PM ET -- CAMBRIDGE, Mass. , Jan. 05, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc.
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the 35th Annual J. P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Jan. 03, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Craig Wheeler , President and CEO, will present at the 35th Annual J. P.
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Positive Top-Line Phase 3 Results for M923, a Proposed HUMIRA® (adalimumab) Biosimilar
CAMBRIDGE, Mass. , Nov. 29, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that the confirmatory Phase 3 clinical study of M923, a biosimilar HUMIRA ® (adalimumab) candidate developed in collaboration with Baxalta, now part of Shire plc, in patients with
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Publication on the Design of M230, a Novel Autoimmune Disease Drug Candidate, in Science Translational Medicine
Data show M230's ability to block immune complex-mediated damage and robust efficacy in preclinical
View HTML